Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

35.12 +0.37 (+1.05%)

Streaming Delayed Price Updated: 10:26 AM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? ↗

September 21, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) announced

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 21, 2023

Via Benzinga

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

September 21, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Analyst Ratings for Travere Therapeutics ↗

September 06, 2023

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

August 18, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Expert Ratings for Travere Therapeutics ↗

July 18, 2023

Via Benzinga

Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 21, 2023

U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know ↗

September 19, 2023

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug ↗

September 08, 2023

Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.

Via Benzinga

Analyst Ratings for Travere Therapeutics ↗

June 07, 2023

Via Benzinga

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

September 05, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 05, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

August 31, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

August 24, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc. ↗

August 10, 2023

San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Travere Therapeutics Reports Second Quarter 2023 Financial Results

August 03, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Small-Cap Stocks That Could Be Big-Time Winners ↗

July 22, 2023

These stocks come with significant risks. But they could generate huge returns over time.

Via The Motley Fool

Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan ↗

July 21, 2023

Travere Therapeutics shares have lost nearly 30% since early May.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Travere Therapeutics to Report Second Quarter 2023 Financial Results

July 20, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗

July 17, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

July 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 17, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗

July 05, 2023

Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.

Via Investor's Business Daily

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

June 08, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.